Followers | 813 |
Posts | 71331 |
Boards Moderated | 2 |
Alias Born | 01/30/2003 |
Tuesday, November 17, 2015 6:11:14 PM
In other news, major shareholder Vivo Ventures Vii, Llc sold 390,572 shares of MEI Pharma stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $1.84, for a total value of $718,652.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
MEIP has been the topic of several research reports. Wedbush restated a “hold” rating on shares of MEI Pharma in a research report on Friday, September 4th. Cowen and Company reiterated a “buy” rating on shares of MEI Pharma in a research report on Wednesday, October 7th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of MEI Pharma in a report on Wednesday, September 2nd.
MEI Pharma (NASDAQ:MEIP) traded down 0.7349% during midday trading on Tuesday, hitting $1.6478. 233,965 shares of the stock traded hands. The company’s market cap is $56.28 million. The firm’s 50-day moving average is $1.73 and its 200-day moving average is $1.78. MEI Pharma has a 52-week low of $1.47 and a 52-week high of $7.14.
MEI Pharma (NASDAQ:MEIP) last issued its quarterly earnings results on Wednesday, September 2nd. The company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. Analysts predict that MEI Pharma will post ($0.67) EPS for the current year.
MEI Pharma, Inc. is an oncology business. The Firm is concentrated on the clinical development of drugs and treatments for treatment of cancer. The business ‘s portfolio of clinical drug candidates includes Pracinostat, ME- PWT143 and 344. Pracinostat is an orally available histone deacetylase (NASDAQ:MEIP) inhibitor indicated for the treatment of hematologic disorders that are advanced, like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-established mitochondrial inhibitor targeting a mitochondrial element of the terminal respiratory chain complex. PWT143 is an oral inhibitor -kinase (PI3K) delta, a molecular target that plays an essential role in the proliferation and survival of hematologic cancer cells. Pracinostat continues to be examined in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
http://midsouthnewz.com/mei-pharma-receives-2-25-average-price-target-from-analysts-nasdaqmeip/20829/
Recent MEIP News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/19/2024 09:20:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 09:05:07 PM
- MEI Pharma Reports Fiscal Year End 2024 Cash Position • Business Wire • 09/19/2024 08:01:00 PM
- MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives • Business Wire • 08/12/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:05:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 08:05:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 09:25:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 08:06:33 PM
- MEI Pharma to Consider Strategic Alternatives • Business Wire • 07/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 05:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2024 08:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:02:15 PM
- MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 05/09/2024 08:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:00:47 PM
- MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 • Business Wire • 04/11/2024 12:02:00 PM
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients • Business Wire • 04/11/2024 12:00:00 PM
- MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum • Business Wire • 04/10/2024 12:00:00 PM
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia • Business Wire • 03/26/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/29/2024 05:15:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:00:17 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/20/2024 10:33:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 10:05:14 PM
- MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights • Business Wire • 02/13/2024 10:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:00:08 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM